nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—ABCB1—ovarian cancer	0.293	1	CbGaD
Dapagliflozin—UGT2B7—Epirubicin—ovarian cancer	0.136	0.33	CbGbCtD
Dapagliflozin—ABCB1—Topotecan—ovarian cancer	0.0464	0.113	CbGbCtD
Dapagliflozin—ABCB1—Vinorelbine—ovarian cancer	0.0327	0.0794	CbGbCtD
Dapagliflozin—CYP2D6—Vinorelbine—ovarian cancer	0.0308	0.0748	CbGbCtD
Dapagliflozin—CYP3A4—Topotecan—ovarian cancer	0.0278	0.0676	CbGbCtD
Dapagliflozin—CYP2C9—Paclitaxel—ovarian cancer	0.0237	0.0575	CbGbCtD
Dapagliflozin—ABCB1—Paclitaxel—ovarian cancer	0.023	0.0558	CbGbCtD
Dapagliflozin—CYP3A4—Vinorelbine—ovarian cancer	0.0196	0.0476	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—ovarian cancer	0.0166	0.0404	CbGbCtD
Dapagliflozin—CYP3A4—Paclitaxel—ovarian cancer	0.0138	0.0334	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—ovarian cancer	0.0124	0.0301	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—ovarian cancer	0.0117	0.0283	CbGbCtD
Dapagliflozin—CYP3A4—Docetaxel—ovarian cancer	0.00995	0.0242	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—ovarian cancer	0.00742	0.018	CbGbCtD
Dapagliflozin—SLC5A1—epithelium—ovarian cancer	0.00285	0.118	CbGeAlD
Dapagliflozin—SLC5A1—endometrium—ovarian cancer	0.00256	0.106	CbGeAlD
Dapagliflozin—SLC5A2—vagina—ovarian cancer	0.00253	0.105	CbGeAlD
Dapagliflozin—Canagliflozin—ABCB1—ovarian cancer	0.00246	1	CrCbGaD
Dapagliflozin—SLC5A2—testis—ovarian cancer	0.00226	0.0937	CbGeAlD
Dapagliflozin—SLC5A1—vagina—ovarian cancer	0.00192	0.0796	CbGeAlD
Dapagliflozin—SLC5A1—testis—ovarian cancer	0.00171	0.071	CbGeAlD
Dapagliflozin—UGT2B7—female reproductive system—ovarian cancer	0.00108	0.0446	CbGeAlD
Dapagliflozin—UGT2B7—testis—ovarian cancer	0.000868	0.036	CbGeAlD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—ovarian cancer	0.000841	0.00477	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Epirubicin—ovarian cancer	0.000808	0.00458	CcSEcCtD
Dapagliflozin—Angina pectoris—Vinorelbine—ovarian cancer	0.00079	0.00448	CcSEcCtD
Dapagliflozin—Urine output increased—Paclitaxel—ovarian cancer	0.000786	0.00446	CcSEcCtD
Dapagliflozin—Neoplasm—Paclitaxel—ovarian cancer	0.000786	0.00446	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—ovarian cancer	0.000747	0.00424	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Melphalan—ovarian cancer	0.000733	0.00416	CcSEcCtD
Dapagliflozin—Phlebitis—Paclitaxel—ovarian cancer	0.000732	0.00415	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Melphalan—ovarian cancer	0.00073	0.00414	CcSEcCtD
Dapagliflozin—Urethral disorder—Melphalan—ovarian cancer	0.000728	0.00413	CcSEcCtD
Dapagliflozin—Infestation—Vinorelbine—ovarian cancer	0.000723	0.0041	CcSEcCtD
Dapagliflozin—Infestation NOS—Vinorelbine—ovarian cancer	0.000723	0.0041	CcSEcCtD
Dapagliflozin—Polyuria—Paclitaxel—ovarian cancer	0.000718	0.00408	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Vinorelbine—ovarian cancer	0.000712	0.00404	CcSEcCtD
Dapagliflozin—Myocardial infarction—Vinorelbine—ovarian cancer	0.000708	0.00402	CcSEcCtD
Dapagliflozin—Lung disorder—Epirubicin—ovarian cancer	0.000702	0.00398	CcSEcCtD
Dapagliflozin—CYP2A6—vagina—ovarian cancer	0.000697	0.0289	CbGeAlD
Dapagliflozin—Angioedema—Chlorambucil—ovarian cancer	0.000678	0.00384	CcSEcCtD
Dapagliflozin—Neoplasm—Docetaxel—ovarian cancer	0.000666	0.00378	CcSEcCtD
Dapagliflozin—Malnutrition—Topotecan—ovarian cancer	0.00066	0.00375	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—ovarian cancer	0.00065	0.00368	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Paclitaxel—ovarian cancer	0.000646	0.00367	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Paclitaxel—ovarian cancer	0.000644	0.00365	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—ovarian cancer	0.000643	0.00365	CcSEcCtD
Dapagliflozin—Back pain—Topotecan—ovarian cancer	0.000639	0.00362	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vinorelbine—ovarian cancer	0.000638	0.00362	CcSEcCtD
Dapagliflozin—Hyponatraemia—Paclitaxel—ovarian cancer	0.000633	0.00359	CcSEcCtD
Dapagliflozin—Pain in extremity—Paclitaxel—ovarian cancer	0.000631	0.00358	CcSEcCtD
Dapagliflozin—Phlebitis—Docetaxel—ovarian cancer	0.000621	0.00352	CcSEcCtD
Dapagliflozin—Angioedema—Topotecan—ovarian cancer	0.000603	0.00342	CcSEcCtD
Dapagliflozin—Infection—Chlorambucil—ovarian cancer	0.000601	0.00341	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—ovarian cancer	0.000595	0.00338	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Paclitaxel—ovarian cancer	0.000591	0.00335	CcSEcCtD
Dapagliflozin—Dehydration—Paclitaxel—ovarian cancer	0.000587	0.00333	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—ovarian cancer	0.000582	0.0033	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Paclitaxel—ovarian cancer	0.000576	0.00327	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—ovarian cancer	0.000569	0.00323	CcSEcCtD
Dapagliflozin—Malnutrition—Vinorelbine—ovarian cancer	0.000565	0.0032	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Paclitaxel—ovarian cancer	0.000564	0.0032	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000558	0.00317	CcSEcCtD
Dapagliflozin—Discomfort—Topotecan—ovarian cancer	0.000555	0.00315	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000547	0.0031	CcSEcCtD
Dapagliflozin—Back pain—Vinorelbine—ovarian cancer	0.000546	0.0031	CcSEcCtD
Dapagliflozin—Influenza—Paclitaxel—ovarian cancer	0.000545	0.00309	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Topotecan—ovarian cancer	0.000539	0.00306	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000538	0.00305	CcSEcCtD
Dapagliflozin—CYP1A1—epithelium—ovarian cancer	0.000538	0.0223	CbGeAlD
Dapagliflozin—Hyponatraemia—Docetaxel—ovarian cancer	0.000537	0.00305	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—ovarian cancer	0.000536	0.00304	CcSEcCtD
Dapagliflozin—Infection—Topotecan—ovarian cancer	0.000535	0.00304	CcSEcCtD
Dapagliflozin—Pain in extremity—Docetaxel—ovarian cancer	0.000535	0.00303	CcSEcCtD
Dapagliflozin—CYP1A1—uterine cervix—ovarian cancer	0.000533	0.0221	CbGeAlD
Dapagliflozin—Anaphylactic shock—Melphalan—ovarian cancer	0.000528	0.00299	CcSEcCtD
Dapagliflozin—Oedema—Melphalan—ovarian cancer	0.000528	0.00299	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—ovarian cancer	0.000527	0.00299	CcSEcCtD
Dapagliflozin—Infection—Melphalan—ovarian cancer	0.000524	0.00297	CcSEcCtD
Dapagliflozin—Skin disorder—Topotecan—ovarian cancer	0.000523	0.00297	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000523	0.00296	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Topotecan—ovarian cancer	0.000521	0.00296	CcSEcCtD
Dapagliflozin—Angioedema—Vinorelbine—ovarian cancer	0.000516	0.00293	CcSEcCtD
Dapagliflozin—Skin disorder—Melphalan—ovarian cancer	0.000513	0.00291	CcSEcCtD
Dapagliflozin—Dysuria—Paclitaxel—ovarian cancer	0.00051	0.00289	CcSEcCtD
Dapagliflozin—Pollakiuria—Paclitaxel—ovarian cancer	0.000504	0.00286	CcSEcCtD
Dapagliflozin—Dehydration—Docetaxel—ovarian cancer	0.000497	0.00282	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—ovarian cancer	0.000496	0.00281	CcSEcCtD
Dapagliflozin—Hypotension—Melphalan—ovarian cancer	0.000493	0.0028	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Docetaxel—ovarian cancer	0.000488	0.00277	CcSEcCtD
Dapagliflozin—Hypertension—Vinorelbine—ovarian cancer	0.000488	0.00277	CcSEcCtD
Dapagliflozin—Infestation NOS—Paclitaxel—ovarian cancer	0.000486	0.00276	CcSEcCtD
Dapagliflozin—Infestation—Paclitaxel—ovarian cancer	0.000486	0.00276	CcSEcCtD
Dapagliflozin—Urticaria—Chlorambucil—ovarian cancer	0.000481	0.00273	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000479	0.00272	CcSEcCtD
Dapagliflozin—Body temperature increased—Chlorambucil—ovarian cancer	0.000479	0.00271	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Docetaxel—ovarian cancer	0.000478	0.00271	CcSEcCtD
Dapagliflozin—Renal failure—Paclitaxel—ovarian cancer	0.000478	0.00271	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000478	0.00271	CcSEcCtD
Dapagliflozin—Myocardial infarction—Paclitaxel—ovarian cancer	0.000477	0.0027	CcSEcCtD
Dapagliflozin—Discomfort—Vinorelbine—ovarian cancer	0.000475	0.0027	CcSEcCtD
Dapagliflozin—Urinary tract infection—Paclitaxel—ovarian cancer	0.000473	0.00268	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—ovarian cancer	0.000469	0.00266	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—ovarian cancer	0.000469	0.00266	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000465	0.00264	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000461	0.00262	CcSEcCtD
Dapagliflozin—Constipation—Topotecan—ovarian cancer	0.000461	0.00261	CcSEcCtD
Dapagliflozin—Infection—Vinorelbine—ovarian cancer	0.000458	0.0026	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000456	0.00258	CcSEcCtD
Dapagliflozin—Angina pectoris—Docetaxel—ovarian cancer	0.00045	0.00255	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—ovarian cancer	0.000449	0.00255	CcSEcCtD
Dapagliflozin—Skin disorder—Vinorelbine—ovarian cancer	0.000448	0.00254	CcSEcCtD
Dapagliflozin—Hypersensitivity—Chlorambucil—ovarian cancer	0.000446	0.00253	CcSEcCtD
Dapagliflozin—CYP1A1—uterus—ovarian cancer	0.000444	0.0184	CbGeAlD
Dapagliflozin—Blood urea increased—Doxorubicin—ovarian cancer	0.000434	0.00246	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—ovarian cancer	0.000434	0.00246	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000431	0.00245	CcSEcCtD
Dapagliflozin—Hypotension—Vinorelbine—ovarian cancer	0.000431	0.00244	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000429	0.00243	CcSEcCtD
Dapagliflozin—Urticaria—Topotecan—ovarian cancer	0.000428	0.00243	CcSEcCtD
Dapagliflozin—Urethral disorder—Paclitaxel—ovarian cancer	0.000428	0.00243	CcSEcCtD
Dapagliflozin—Body temperature increased—Topotecan—ovarian cancer	0.000426	0.00242	CcSEcCtD
Dapagliflozin—Urticaria—Melphalan—ovarian cancer	0.000419	0.00238	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—ovarian cancer	0.000419	0.00238	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—ovarian cancer	0.000416	0.00236	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—ovarian cancer	0.000415	0.00235	CcSEcCtD
Dapagliflozin—Infestation NOS—Docetaxel—ovarian cancer	0.000412	0.00234	CcSEcCtD
Dapagliflozin—Infestation—Docetaxel—ovarian cancer	0.000412	0.00234	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000406	0.0023	CcSEcCtD
Dapagliflozin—Renal failure—Docetaxel—ovarian cancer	0.000405	0.0023	CcSEcCtD
Dapagliflozin—Myocardial infarction—Docetaxel—ovarian cancer	0.000404	0.00229	CcSEcCtD
Dapagliflozin—CYP1A1—female reproductive system—ovarian cancer	0.000399	0.0166	CbGeAlD
Dapagliflozin—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000398	0.00226	CcSEcCtD
Dapagliflozin—Hypersensitivity—Topotecan—ovarian cancer	0.000397	0.00225	CcSEcCtD
Dapagliflozin—Constipation—Vinorelbine—ovarian cancer	0.000394	0.00224	CcSEcCtD
Dapagliflozin—Hypersensitivity—Melphalan—ovarian cancer	0.000389	0.00221	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—ovarian cancer	0.000387	0.0022	CcSEcCtD
Dapagliflozin—CYP2C9—female reproductive system—ovarian cancer	0.000384	0.0159	CbGeAlD
Dapagliflozin—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000384	0.00218	CcSEcCtD
Dapagliflozin—Malnutrition—Paclitaxel—ovarian cancer	0.00038	0.00216	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—ovarian cancer	0.00037	0.0021	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000368	0.00209	CcSEcCtD
Dapagliflozin—Back pain—Paclitaxel—ovarian cancer	0.000367	0.00208	CcSEcCtD
Dapagliflozin—Urticaria—Vinorelbine—ovarian cancer	0.000366	0.00208	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—ovarian cancer	0.000365	0.00207	CcSEcCtD
Dapagliflozin—Body temperature increased—Vinorelbine—ovarian cancer	0.000364	0.00207	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—ovarian cancer	0.000364	0.00206	CcSEcCtD
Dapagliflozin—CYP1A1—female gonad—ovarian cancer	0.000363	0.0151	CbGeAlD
Dapagliflozin—Urethral disorder—Docetaxel—ovarian cancer	0.000363	0.00206	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—ovarian cancer	0.000362	0.00205	CcSEcCtD
Dapagliflozin—CYP1A1—vagina—ovarian cancer	0.000361	0.015	CbGeAlD
Dapagliflozin—Pain in extremity—Epirubicin—ovarian cancer	0.000361	0.00205	CcSEcCtD
Dapagliflozin—Nausea—Chlorambucil—ovarian cancer	0.00036	0.00204	CcSEcCtD
Dapagliflozin—Dizziness—Topotecan—ovarian cancer	0.000356	0.00202	CcSEcCtD
Dapagliflozin—ABCB1—myometrium—ovarian cancer	0.000356	0.0148	CbGeAlD
Dapagliflozin—Angioedema—Paclitaxel—ovarian cancer	0.000347	0.00197	CcSEcCtD
Dapagliflozin—ABCB1—embryo—ovarian cancer	0.000342	0.0142	CbGeAlD
Dapagliflozin—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000342	0.00194	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000341	0.00193	CcSEcCtD
Dapagliflozin—Rash—Topotecan—ovarian cancer	0.00034	0.00193	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinorelbine—ovarian cancer	0.00034	0.00193	CcSEcCtD
Dapagliflozin—Dermatitis—Topotecan—ovarian cancer	0.000339	0.00193	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—ovarian cancer	0.000338	0.00192	CcSEcCtD
Dapagliflozin—Headache—Topotecan—ovarian cancer	0.000338	0.00192	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—ovarian cancer	0.000335	0.0019	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—ovarian cancer	0.000335	0.0019	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—ovarian cancer	0.000334	0.00189	CcSEcCtD
Dapagliflozin—Rash—Melphalan—ovarian cancer	0.000333	0.00189	CcSEcCtD
Dapagliflozin—Dermatitis—Melphalan—ovarian cancer	0.000332	0.00189	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000329	0.00187	CcSEcCtD
Dapagliflozin—Hypertension—Paclitaxel—ovarian cancer	0.000328	0.00186	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—ovarian cancer	0.000323	0.00183	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—ovarian cancer	0.000322	0.00183	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000321	0.00182	CcSEcCtD
Dapagliflozin—Nausea—Topotecan—ovarian cancer	0.00032	0.00182	CcSEcCtD
Dapagliflozin—Discomfort—Paclitaxel—ovarian cancer	0.00032	0.00181	CcSEcCtD
Dapagliflozin—Nausea—Melphalan—ovarian cancer	0.000313	0.00178	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000313	0.00177	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—ovarian cancer	0.000312	0.00177	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—ovarian cancer	0.000311	0.00177	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—ovarian cancer	0.00031	0.00176	CcSEcCtD
Dapagliflozin—Oedema—Paclitaxel—ovarian cancer	0.00031	0.00176	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00031	0.00176	CcSEcCtD
Dapagliflozin—Infection—Paclitaxel—ovarian cancer	0.000308	0.00175	CcSEcCtD
Dapagliflozin—Dizziness—Vinorelbine—ovarian cancer	0.000305	0.00173	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000305	0.00173	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—ovarian cancer	0.000304	0.00172	CcSEcCtD
Dapagliflozin—Skin disorder—Paclitaxel—ovarian cancer	0.000301	0.00171	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Paclitaxel—ovarian cancer	0.0003	0.0017	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000298	0.00169	CcSEcCtD
Dapagliflozin—CYP3A4—female reproductive system—ovarian cancer	0.000293	0.0122	CbGeAlD
Dapagliflozin—Dysuria—Epirubicin—ovarian cancer	0.000291	0.00165	CcSEcCtD
Dapagliflozin—Rash—Vinorelbine—ovarian cancer	0.000291	0.00165	CcSEcCtD
Dapagliflozin—Dermatitis—Vinorelbine—ovarian cancer	0.00029	0.00165	CcSEcCtD
Dapagliflozin—Hypotension—Paclitaxel—ovarian cancer	0.00029	0.00164	CcSEcCtD
Dapagliflozin—Headache—Vinorelbine—ovarian cancer	0.000289	0.00164	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—ovarian cancer	0.000288	0.00164	CcSEcCtD
Dapagliflozin—CYP2D6—female reproductive system—ovarian cancer	0.000288	0.012	CbGeAlD
Dapagliflozin—Pollakiuria—Epirubicin—ovarian cancer	0.000288	0.00163	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—ovarian cancer	0.000281	0.00159	CcSEcCtD
Dapagliflozin—ABCB1—epithelium—ovarian cancer	0.000279	0.0116	CbGeAlD
Dapagliflozin—Hypertension—Docetaxel—ovarian cancer	0.000278	0.00158	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—ovarian cancer	0.000278	0.00158	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—ovarian cancer	0.000278	0.00158	CcSEcCtD
Dapagliflozin—ABCB1—uterine cervix—ovarian cancer	0.000277	0.0115	CbGeAlD
Dapagliflozin—Nausea—Vinorelbine—ovarian cancer	0.000274	0.00155	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—ovarian cancer	0.000273	0.00155	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000272	0.00154	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—ovarian cancer	0.00027	0.00153	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—ovarian cancer	0.00027	0.00153	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000268	0.00152	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—ovarian cancer	0.000266	0.00151	CcSEcCtD
Dapagliflozin—Constipation—Paclitaxel—ovarian cancer	0.000265	0.0015	CcSEcCtD
Dapagliflozin—ABCB1—decidua—ovarian cancer	0.000264	0.0109	CbGeAlD
Dapagliflozin—Oedema—Docetaxel—ovarian cancer	0.000263	0.00149	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000263	0.00149	CcSEcCtD
Dapagliflozin—CYP2D6—female gonad—ovarian cancer	0.000262	0.0109	CbGeAlD
Dapagliflozin—Infection—Docetaxel—ovarian cancer	0.000261	0.00148	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—ovarian cancer	0.000257	0.00146	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—ovarian cancer	0.000257	0.00146	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—ovarian cancer	0.000255	0.00145	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—ovarian cancer	0.000253	0.00143	CcSEcCtD
Dapagliflozin—ABCB1—endometrium—ovarian cancer	0.00025	0.0104	CbGeAlD
Dapagliflozin—Urinary tract infection—Doxorubicin—ovarian cancer	0.00025	0.00142	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—ovarian cancer	0.000246	0.0014	CcSEcCtD
Dapagliflozin—Urticaria—Paclitaxel—ovarian cancer	0.000246	0.0014	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—ovarian cancer	0.000246	0.00139	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—ovarian cancer	0.000245	0.00139	CcSEcCtD
Dapagliflozin—Body temperature increased—Paclitaxel—ovarian cancer	0.000245	0.00139	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—ovarian cancer	0.000245	0.00139	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—ovarian cancer	0.000234	0.00969	CbGeAlD
Dapagliflozin—CYP2D6—testis—ovarian cancer	0.000233	0.00966	CbGeAlD
Dapagliflozin—ABCB1—gonad—ovarian cancer	0.000232	0.00964	CbGeAlD
Dapagliflozin—ABCB1—uterus—ovarian cancer	0.000231	0.00958	CbGeAlD
Dapagliflozin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000228	0.0013	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000228	0.00129	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000227	0.00129	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000227	0.00129	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—ovarian cancer	0.000226	0.00128	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—ovarian cancer	0.000225	0.00128	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—ovarian cancer	0.000217	0.00123	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—ovarian cancer	0.00021	0.00119	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—ovarian cancer	0.000208	0.00118	CcSEcCtD
Dapagliflozin—ABCB1—female reproductive system—ovarian cancer	0.000207	0.00861	CbGeAlD
Dapagliflozin—Dizziness—Paclitaxel—ovarian cancer	0.000205	0.00116	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—ovarian cancer	0.000201	0.00114	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—ovarian cancer	0.000196	0.00813	CbGeAlD
Dapagliflozin—Rash—Paclitaxel—ovarian cancer	0.000195	0.00111	CcSEcCtD
Dapagliflozin—Dermatitis—Paclitaxel—ovarian cancer	0.000195	0.00111	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—ovarian cancer	0.000194	0.0011	CcSEcCtD
Dapagliflozin—Headache—Paclitaxel—ovarian cancer	0.000194	0.0011	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—ovarian cancer	0.000194	0.0011	CcSEcCtD
Dapagliflozin—ABCB1—female gonad—ovarian cancer	0.000189	0.00783	CbGeAlD
Dapagliflozin—ABCB1—vagina—ovarian cancer	0.000188	0.00779	CbGeAlD
Dapagliflozin—Hypertension—Epirubicin—ovarian cancer	0.000188	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Paclitaxel—ovarian cancer	0.000184	0.00104	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000184	0.00104	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—ovarian cancer	0.000183	0.00104	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—ovarian cancer	0.000177	0.00101	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—ovarian cancer	0.000177	0.00101	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—ovarian cancer	0.000176	0.000999	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—ovarian cancer	0.000174	0.000986	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—ovarian cancer	0.000174	0.000984	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—ovarian cancer	0.000172	0.000977	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—ovarian cancer	0.000171	0.000972	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00017	0.000964	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—ovarian cancer	0.000169	0.000959	CcSEcCtD
Dapagliflozin—ABCB1—testis—ovarian cancer	0.000167	0.00695	CbGeAlD
Dapagliflozin—Rash—Docetaxel—ovarian cancer	0.000166	0.00094	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—ovarian cancer	0.000166	0.00094	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—ovarian cancer	0.000166	0.000939	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—ovarian cancer	0.000165	0.000934	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—ovarian cancer	0.000164	0.000931	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000164	0.000931	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—ovarian cancer	0.000163	0.000924	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—ovarian cancer	0.000159	0.000904	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000159	0.0009	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—ovarian cancer	0.000156	0.000886	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—ovarian cancer	0.000153	0.000869	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000153	0.000868	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—ovarian cancer	0.000152	0.00086	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000142	0.000803	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—ovarian cancer	0.000141	0.000799	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—ovarian cancer	0.00014	0.000796	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—ovarian cancer	0.00014	0.000795	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—ovarian cancer	0.000131	0.000741	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—ovarian cancer	0.00013	0.000739	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—ovarian cancer	0.00013	0.000736	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—ovarian cancer	0.000121	0.00504	CbGeAlD
Dapagliflozin—Hypersensitivity—Doxorubicin—ovarian cancer	0.000121	0.000686	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—ovarian cancer	0.000117	0.000665	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—ovarian cancer	0.000112	0.000634	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—ovarian cancer	0.000112	0.000634	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—ovarian cancer	0.000111	0.00063	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—ovarian cancer	0.000108	0.000615	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—ovarian cancer	0.000105	0.000597	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—ovarian cancer	0.000103	0.000587	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—ovarian cancer	0.000103	0.000586	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—ovarian cancer	0.000103	0.000583	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—ovarian cancer	9.74e-05	0.000553	CcSEcCtD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.08e-05	0.00044	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.06e-05	0.000438	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.98e-05	0.00043	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPP1CC—ovarian cancer	3.98e-05	0.000429	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—BRIP1—ovarian cancer	3.98e-05	0.000429	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NME2—ovarian cancer	3.96e-05	0.000428	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PIK3CA—ovarian cancer	3.93e-05	0.000424	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NME2—ovarian cancer	3.93e-05	0.000424	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—STAT3—ovarian cancer	3.78e-05	0.000407	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—STAT3—ovarian cancer	3.78e-05	0.000407	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—ovarian cancer	3.77e-05	0.000407	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—ovarian cancer	3.77e-05	0.000407	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.76e-05	0.000406	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.76e-05	0.000406	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.64e-05	0.000393	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—ovarian cancer	3.64e-05	0.000392	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CD—ovarian cancer	3.62e-05	0.000391	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MAPK3—ovarian cancer	3.61e-05	0.000389	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MAPK3—ovarian cancer	3.61e-05	0.000389	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTEN—ovarian cancer	3.54e-05	0.000382	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTEN—ovarian cancer	3.54e-05	0.000382	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—ovarian cancer	3.51e-05	0.000379	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—ovarian cancer	3.51e-05	0.000379	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IL6—ovarian cancer	3.48e-05	0.000376	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—FASN—ovarian cancer	3.47e-05	0.000375	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—YAP1—ovarian cancer	3.46e-05	0.000374	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MAPK1—ovarian cancer	3.43e-05	0.00037	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MAPK1—ovarian cancer	3.43e-05	0.00037	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—ovarian cancer	3.43e-05	0.00037	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—ovarian cancer	3.43e-05	0.00037	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.43e-05	0.00037	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SLC5A5—ovarian cancer	3.42e-05	0.000369	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYTB—ovarian cancer	3.39e-05	0.000366	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	3.36e-05	0.000363	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NME2—ovarian cancer	3.36e-05	0.000362	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.33e-05	0.00036	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.32e-05	0.000358	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SLC2A1—ovarian cancer	3.3e-05	0.000356	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PIK3CA—ovarian cancer	3.29e-05	0.000355	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—ovarian cancer	3.24e-05	0.00035	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—ovarian cancer	3.24e-05	0.00035	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—ovarian cancer	3.21e-05	0.000346	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP1B1—ovarian cancer	3.16e-05	0.000341	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CB—ovarian cancer	3.16e-05	0.000341	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.01e-05	0.000325	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PIK3CA—ovarian cancer	2.98e-05	0.000321	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PIK3CA—ovarian cancer	2.98e-05	0.000321	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.97e-05	0.00032	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.97e-05	0.00032	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.92e-05	0.000315	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.85e-05	0.000307	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—FASN—ovarian cancer	2.82e-05	0.000305	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPP2R1A—ovarian cancer	2.81e-05	0.000303	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC5A5—ovarian cancer	2.78e-05	0.0003	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—ovarian cancer	2.76e-05	0.000297	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—ovarian cancer	2.76e-05	0.000297	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—ovarian cancer	2.73e-05	0.000295	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.72e-05	0.000293	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.72e-05	0.000293	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYTB—ovarian cancer	2.71e-05	0.000292	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.71e-05	0.000292	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—ovarian cancer	2.69e-05	0.00029	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC2A1—ovarian cancer	2.68e-05	0.000289	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—YAP1—ovarian cancer	2.67e-05	0.000288	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.65e-05	0.000286	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IL6—ovarian cancer	2.64e-05	0.000285	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IL6—ovarian cancer	2.64e-05	0.000285	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.63e-05	0.000283	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.63e-05	0.000283	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ABCB1—ovarian cancer	2.61e-05	0.000281	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NME2—ovarian cancer	2.59e-05	0.00028	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.58e-05	0.000279	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1B1—ovarian cancer	2.57e-05	0.000277	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TYMS—ovarian cancer	2.56e-05	0.000276	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.56e-05	0.000276	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYTB—ovarian cancer	2.55e-05	0.000276	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYTB—ovarian cancer	2.53e-05	0.000273	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—ovarian cancer	2.49e-05	0.000269	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—ovarian cancer	2.49e-05	0.000269	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.49e-05	0.000269	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.47e-05	0.000267	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—ovarian cancer	2.43e-05	0.000263	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—ovarian cancer	2.43e-05	0.000263	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.37e-05	0.000256	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—BRIP1—ovarian cancer	2.37e-05	0.000256	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.32e-05	0.00025	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	2.28e-05	0.000246	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.27e-05	0.000245	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.25e-05	0.000243	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.23e-05	0.000241	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.23e-05	0.000241	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.21e-05	0.000239	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.21e-05	0.000239	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—FASN—ovarian cancer	2.18e-05	0.000235	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYTB—ovarian cancer	2.16e-05	0.000233	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.16e-05	0.000233	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC5A5—ovarian cancer	2.14e-05	0.000231	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.13e-05	0.00023	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ABCB1—ovarian cancer	2.12e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.11e-05	0.000228	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TYMS—ovarian cancer	2.08e-05	0.000224	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.07e-05	0.000224	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC2A1—ovarian cancer	2.07e-05	0.000223	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CAV1—ovarian cancer	2.06e-05	0.000222	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—ovarian cancer	2.04e-05	0.00022	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—ovarian cancer	2.04e-05	0.00022	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.03e-05	0.000219	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.03e-05	0.000219	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—YAP1—ovarian cancer	1.99e-05	0.000215	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1B1—ovarian cancer	1.98e-05	0.000214	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.97e-05	0.000212	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—ovarian cancer	1.93e-05	0.000208	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.91e-05	0.000207	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.89e-05	0.000204	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.89e-05	0.000204	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CG—ovarian cancer	1.88e-05	0.000203	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.76e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPP2R1A—ovarian cancer	1.76e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.73e-05	0.000187	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.7e-05	0.000184	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CAV1—ovarian cancer	1.68e-05	0.000181	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYTB—ovarian cancer	1.67e-05	0.00018	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CD—ovarian cancer	1.65e-05	0.000178	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—ovarian cancer	1.63e-05	0.000176	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—FASN—ovarian cancer	1.62e-05	0.000175	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.61e-05	0.000174	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TYMS—ovarian cancer	1.6e-05	0.000173	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.6e-05	0.000173	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.59e-05	0.000172	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—YAP1—ovarian cancer	1.59e-05	0.000171	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—ovarian cancer	1.57e-05	0.00017	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.54e-05	0.000166	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—ovarian cancer	1.53e-05	0.000165	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.51e-05	0.000163	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—YAP1—ovarian cancer	1.5e-05	0.000162	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—YAP1—ovarian cancer	1.48e-05	0.00016	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.48e-05	0.000159	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.47e-05	0.000158	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.46e-05	0.000157	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.46e-05	0.000157	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CB—ovarian cancer	1.44e-05	0.000155	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.44e-05	0.000155	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.38e-05	0.000149	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CD—ovarian cancer	1.34e-05	0.000145	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	1.31e-05	0.000141	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.3e-05	0.000141	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—FASN—ovarian cancer	1.29e-05	0.00014	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CAV1—ovarian cancer	1.29e-05	0.000139	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.29e-05	0.000139	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.27e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—YAP1—ovarian cancer	1.27e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.25e-05	0.000135	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—ovarian cancer	1.24e-05	0.000134	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.23e-05	0.000133	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—FASN—ovarian cancer	1.22e-05	0.000132	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—ovarian cancer	1.22e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—FASN—ovarian cancer	1.21e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.2e-05	0.00013	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—ovarian cancer	1.19e-05	0.000129	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.19e-05	0.000128	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.18e-05	0.000127	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—ovarian cancer	1.18e-05	0.000127	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—ovarian cancer	1.17e-05	0.000126	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.16e-05	0.000125	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.15e-05	0.000124	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.13e-05	0.000121	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.11e-05	0.00012	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.1e-05	0.000119	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.1e-05	0.000119	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.05e-05	0.000113	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—ovarian cancer	1.03e-05	0.000112	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—FASN—ovarian cancer	1.03e-05	0.000112	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.02e-05	0.00011	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—ovarian cancer	1.01e-05	0.000109	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.86e-06	0.000106	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A1—ovarian cancer	9.82e-06	0.000106	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—YAP1—ovarian cancer	9.79e-06	0.000106	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	9.77e-06	0.000105	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.72e-06	0.000105	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAV1—ovarian cancer	9.62e-06	0.000104	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.62e-06	0.000104	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—ovarian cancer	9.54e-06	0.000103	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1B1—ovarian cancer	9.42e-06	0.000102	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.19e-06	9.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—ovarian cancer	9.15e-06	9.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—ovarian cancer	9.07e-06	9.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—ovarian cancer	9.01e-06	9.73e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—ovarian cancer	8.99e-06	9.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—ovarian cancer	8.91e-06	9.62e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—ovarian cancer	8.77e-06	9.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—ovarian cancer	8.77e-06	9.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	8.35e-06	9.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.31e-06	8.97e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FASN—ovarian cancer	7.98e-06	8.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.85e-06	8.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—ovarian cancer	7.79e-06	8.41e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—ovarian cancer	7.75e-06	8.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—ovarian cancer	7.71e-06	8.31e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAV1—ovarian cancer	7.69e-06	8.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—ovarian cancer	7.61e-06	8.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.58e-06	8.18e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.27e-06	7.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAV1—ovarian cancer	7.24e-06	7.82e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAV1—ovarian cancer	7.18e-06	7.75e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—ovarian cancer	7.17e-06	7.73e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—ovarian cancer	7.13e-06	7.69e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—ovarian cancer	7e-06	7.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.86e-06	7.4e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—ovarian cancer	6.72e-06	7.25e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.6e-06	7.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.54e-06	7.06e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.44e-06	6.95e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—ovarian cancer	6.15e-06	6.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAV1—ovarian cancer	6.14e-06	6.62e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.98e-06	6.46e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—ovarian cancer	5.88e-06	6.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.86e-06	6.33e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—ovarian cancer	5.82e-06	6.28e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—ovarian cancer	5.8e-06	6.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.8e-06	6.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.75e-06	6.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.59e-06	6.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—ovarian cancer	5.5e-06	5.93e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—ovarian cancer	5.36e-06	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—ovarian cancer	5.06e-06	5.45e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—ovarian cancer	5.01e-06	5.41e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.91e-06	5.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAV1—ovarian cancer	4.74e-06	5.11e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—ovarian cancer	4.64e-06	5e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—ovarian cancer	4.49e-06	4.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—ovarian cancer	4.37e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—ovarian cancer	4.33e-06	4.67e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.31e-06	4.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.28e-06	4.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—ovarian cancer	4.09e-06	4.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.79e-06	4.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—ovarian cancer	3.7e-06	3.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—ovarian cancer	3.34e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.31e-06	3.57e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.27e-06	3.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.08e-06	3.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—ovarian cancer	3.06e-06	3.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—ovarian cancer	2.86e-06	3.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—ovarian cancer	2.67e-06	2.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.61e-06	2.82e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—ovarian cancer	2.52e-06	2.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—ovarian cancer	2.5e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—ovarian cancer	2.13e-06	2.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.01e-06	2.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—ovarian cancer	1.65e-06	1.78e-05	CbGpPWpGaD
